BCM
NVO

Bienville Capital Management’s Novo Nordisk NVO Stock Holding History

Bienville Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-12,000
Closed -$254K – 82
2014
Q4 		$254K Buy
+12,000
New +$268K 0.21% 75

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bienville Capital Management's NVO Position: Q1 2015 in Review

Bienville Capital Management sold out of Novo Nordisk (NVO) in Q1 2015, closing a stake of 12,000 shares — an estimated $254K sold.

Bienville Capital Management first reported a position in NVO in Q4 2014 and held it in 1 quarter. The position peaked at $254K in Q4 2014. 505 funds tracked by Wall St. Rank hold NVO as of Q1 2015.

  • Bienville Capital Management reported no remaining Novo Nordisk position as of Q1 2015 after selling out during the quarter.
  • Bienville Capital Management sold 12,000 Novo Nordisk shares in Q1 2015, an estimated $254K.
  • Bienville Capital Management first reported a position in Novo Nordisk in Q4 2014 and held it in 1 quarter.
  • Bienville Capital Management's Novo Nordisk position peaked at $254K in Q4 2014.
  • 505 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2015.

Based on Bienville Capital Management's 13F filing for Q1 2015, filed 13 May 2015.